Matricaria Chamomilla Flowering Top

Dosage for Matricaria Chamomilla Flowering Top is highly individualized and is not based on a standard 'one-size-fits-all' milligram dose. Instead, it is based on the patient's sensitivity and the concentration of the extract.

• Diagnostic Testing: A single drop of the extract (typically 1:10 or 1:20 w/v) is applied to the skin for a prick test. For intradermal testing, a very small volume (0.02 to 0.05 mL) of a highly diluted extract (e.g., 100 PNU/mL) is injected.
• Immunotherapy: The 'Build-up Phase' begins with a very low dose (e.g., 0.1 mL of a 1:10,000 dilution). Doses are increased weekly or bi-weekly until a 'Maintenance Dose' is reached, which is the highest dose the patient can tolerate without a significant local or systemic reaction.

Safety and effectiveness in children have been established, though dosage must be even more conservative. The procedure for skin testing is identical to adults, but the number of simultaneous tests may be limited to prevent excessive discomfort or systemic absorption. Immunotherapy doses for children are generally similar to adult doses but must be adjusted based on the child's weight and the clinician's assessment of risk.

Renal Impairment

Specific dosage adjustments for renal impairment are not provided in the manufacturer's labeling. However, because systemic reactions to allergenic extracts can stress the cardiovascular system, clinicians should exercise caution in patients with severe renal disease who may not tolerate the emergency medications (like epinephrine) used to treat reactions.

Hepatic Impairment

No specific adjustments are required for hepatic impairment, as the metabolism of the extract proteins is not primarily dependent on liver function.

Elderly Patients

Elderly patients (over 65) should be evaluated for cardiovascular stability before administration. The risk of a systemic reaction may be higher if the patient is taking multiple medications for other conditions, such as beta-blockers or ACE inhibitors.

This medication is NEVER self-administered by the patient at home. It must be administered in a clinical setting (such as an allergist's office) equipped with emergency resuscitation equipment.

• Administration: Subcutaneous injection for immunotherapy should be given in the posterior aspect of the upper arm. The site should be rotated between injections.
• Observation: Patients MUST remain in the medical office for at least 30 minutes after any injection to monitor for signs of a systemic allergic reaction.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has elapsed. If more than 7-10 days have passed since the last scheduled build-up dose, the clinician may repeat the previous dose or even go back several steps in the dilution series to ensure safety.

An overdose in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. Signs of 'overdose' are synonymous with an acute systemic allergic reaction, including hives, swelling of the throat, wheezing, and drop in blood pressure. Emergency treatment with epinephrine is required immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

The most common side effects associated with Matricaria Chamomilla Flowering Top are localized to the site of administration. These are expected responses to the allergen and include:

• Wheal and Flare: A raised, itchy bump (wheal) surrounded by redness (flare) at the injection or prick site. This usually appears within 15-20 minutes and resolves within a few hours.
• Local Swelling: Some patients may experience swelling of the upper arm (edema) that can persist for 24 to 48 hours. This is often managed with cold compresses or oral antihistamines.
• Pruritus (Itching): Intense itching at the site of the test or injection.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter at the injection site. This may indicate that the next dose of immunotherapy should be held or reduced.
• Fatigue: Some patients report feeling unusually tired for several hours following an allergy injection.
• Headache: A mild, transient headache may occur after administration.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Cough: A dry, irritating cough that may signal the beginning of a systemic respiratory reaction.

> Warning: Stop taking Matricaria Chamomilla Flowering Top (discontinue the procedure) and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:

1. 1Difficulty Breathing: Wheezing, shortness of breath, or a feeling of tightness in the chest.
2. 2Throat Tightness: A feeling that the throat is closing or difficulty swallowing.
3. 3Hypotension: A sudden drop in blood pressure, which may feel like dizziness, lightheadedness, or fainting.
4. 4Rapid Pulse: A racing heart or palpitations.
5. 5Cyanosis: A bluish tint to the lips or fingernails, indicating low oxygen levels.

With prolonged use of immunotherapy, some patients may develop increased sensitivity to other related plants in the Asteraceae family (cross-sensitization). However, the goal of long-term therapy is usually the opposite: a gradual decrease in sensitivity. There are no known risks of organ toxicity (such as liver or kidney damage) associated with the long-term use of these protein-based extracts.

Most allergenic extracts, including Matricaria Chamomilla Flowering Top, carry a class-wide FDA warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It must only be administered by healthcare providers who are prepared to manage such reactions. Patients with unstable asthma or those taking beta-blockers may be at higher risk for severe outcomes if a reaction occurs. All patients must be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider immediately.

Matricaria Chamomilla Flowering Top extract is a potent biological substance. It is only intended for use by specialists in allergy and immunology. Patients must be aware that while the extract is used to treat allergies, it is itself a concentrated allergen that can trigger the very symptoms it aims to diagnose or treat.

No specific individual black box warning exists solely for Matricaria Chamomilla, but it falls under the general FDA black box warning for all allergenic extracts. The warning emphasizes that systemic reactions are unpredictable and can occur even in patients who have previously tolerated the extract well. Epinephrine (Adrenaline) must be immediately available whenever this extract is used.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Anaphylaxis can occur within minutes of administration. Risk factors include a history of severe asthma, high levels of sensitivity, and the use of certain medications.
• Asthma Status: Patients experiencing an acute asthma flare or those with poorly controlled asthma (FEV1 < 70% of predicted) should not receive immunotherapy injections, as they are at significantly higher risk for fatal bronchospasm during a systemic reaction.
• Asteraceae Cross-Reactivity: Patients with known severe allergies to ragweed, chrysanthemums, or marigolds should be treated with extreme caution, as they may have a high degree of cross-sensitivity to chamomile.

• Pre-Injection Assessment: Before each dose, the clinician will ask if the patient had a delayed reaction to the previous dose and will check for current symptoms of asthma or infection.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is required after every administration.
• Peak Flow Monitoring: For patients with asthma, a peak flow meter may be used before and after injections to ensure lung function is stable.

Patients should generally avoid driving or operating heavy machinery immediately after an injection if they feel dizzy or if they have taken an antihistamine that causes drowsiness. If a systemic reaction occurs, the patient should not drive themselves home.

Alcohol consumption should be avoided on the day of an allergy injection. Alcohol can increase blood flow to the skin and potentially speed up the absorption of the allergen, increasing the risk of a reaction. Furthermore, alcohol can mask the early symptoms of a systemic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider will evaluate whether to continue therapy. If therapy is continued, the dose is typically reduced significantly. Tapering is not required in the traditional sense, as there is no physical dependence, but stopping suddenly will result in the loss of the immunological tolerance built up during treatment.

> Important: Discuss all your medical conditions with your healthcare provider before starting Matricaria Chamomilla Flowering Top.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are generally contraindicated in patients receiving allergenic extracts. Beta-blockers can make a systemic allergic reaction (anaphylaxis) more severe and, more importantly, they can block the effects of epinephrine, the primary treatment for anaphylaxis. This combination can be life-threatening.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions to allergenic extracts or may have a higher risk of hypotension during a reaction.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process emergency medications like epinephrine, potentially leading to dangerous blood pressure spikes if emergency treatment is needed.

• Antihistamines (e.g., Loratadine, Cetirizine): These medications will suppress the skin's response to the extract. For diagnostic skin testing to be accurate, patients must stop taking antihistamines for 3 to 7 days prior to the test. However, antihistamines are often continued during the immunotherapy phase to manage minor local reactions.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the effects of epinephrine, requiring careful management during an emergency.

• Cross-Reactive Foods: Patients allergic to chamomile may also react to foods containing related proteins, such as sunflower seeds, honey (which may contain chamomile pollen), and certain spices. Consuming these foods immediately before or after an injection may increase the total 'allergen load' and trigger a reaction.

• Other Asteraceae Supplements: Taking herbal supplements like Echinacea, Feverfew, or Milk Thistle may increase the risk of a reaction, as these plants are botanically related to chamomile and share similar allergenic proteins.

Matricaria Chamomilla Flowering Top extract does not typically interfere with standard blood chemistry or hematology tests. However, it will directly affect the results of:

• Skin Prick Tests: As intended, it causes a positive result.
• In Vitro IgE Testing (RAST/ImmunoCAP): Clinical use of the extract may eventually lead to changes in circulating IgE and IgG levels, which are monitored to track the progress of immunotherapy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Matricaria Chamomilla Flowering Top must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a baseline FEV1 of less than 70% of predicted or those who have had a recent life-threatening asthma exacerbation. The risk of fatal bronchospasm during a systemic reaction is too high.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The cardiovascular stress of a systemic reaction or the administration of epinephrine could be fatal.
3. 3Hypersensitivity to Constituents: Known previous anaphylactic reaction to any component of the extract, including the stabilizing agents like glycerin or phenol.

Conditions requiring a careful risk-benefit analysis by the allergist include:

• Autoimmune Diseases: There is a theoretical risk that immunotherapy could worsen certain autoimmune conditions by stimulating the immune system.
• Malignancy: Patients with active cancer may have altered immune responses.
• Beta-Blocker Therapy: If the beta-blocker cannot be safely discontinued, the risk of immunotherapy is significantly elevated.

Patients should be screened for sensitivity to the following related substances, as they may cause a cross-allergic reaction with Matricaria Chamomilla:

• Ragweed (Ambrosia)
• Chrysanthemums
• Dahlias
• Marigolds
• Sunflowers
• Arnica

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Matricaria Chamomilla Flowering Top.

Matricaria Chamomilla Flowering Top is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.

• Risk Summary: While immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis (which can cause fetal hypoxia), it is often continued in women who are already on a stable maintenance dose and are tolerating it well.
• Clinical Considerations: Dose escalation should be paused during pregnancy to minimize the risk of a systemic reaction.

It is not known whether the allergenic proteins from the extract are excreted in human milk. However, since these are large proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. The primary concern is the mother's safety; if she has a severe reaction, it could interfere with her ability to breastfeed.

Allergenic extracts are used in children as young as 5 years old. Safety and efficacy are similar to adults, but clinicians must be particularly cautious about the child's ability to communicate early symptoms of a systemic reaction. Children with a history of severe asthma are at the highest risk.

Patients over the age of 65 may have a higher prevalence of cardiovascular disease, which increases the risk of complications if a systemic reaction occurs. Additionally, the elderly are more likely to be taking medications like beta-blockers or ACE inhibitors, which complicate the management of anaphylaxis.

No specific GFR-based dose adjustments are required. However, the patient's overall health and ability to tolerate emergency resuscitation should be considered. Dialysis does not clear the allergenic proteins in any significant way.

No adjustments are necessary for patients with liver disease. The proteins in the extract are processed by general cellular proteolytic pathways rather than specific hepatic enzymes like the CYP450 system.

> Important: Special populations require individualized medical assessment by an allergy specialist.

Matricaria Chamomilla Flowering Top extract acts as an exogenous antigen. In sensitized individuals, the primary allergens (such as the protein Mat c 1) bind to bivalent IgE molecules on the surface of mast cells and basophils. This cross-linking triggers degranulation, releasing histamine, prostaglandin D2, and tryptase. In immunotherapy, the mechanism shifts toward the induction of T-regulatory (Treg) cells, which secrete IL-10 and TGF-beta, suppressing the allergic Th2 response and promoting the production of IgG4 'blocking' antibodies.

The pharmacodynamic response is visible as the 'wheal and flare' reaction. The size of the wheal is generally proportional to the degree of the patient's IgE-mediated sensitivity. The onset of the reaction is rapid (15-20 minutes), and the duration of the localized inflammatory response is typically 2-4 hours, though late-phase reactions can occur 6-12 hours later.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Percutaneous); Moderate (Subcutaneous) |

| Protein Binding | Primarily to specific IgE and IgG4 antibodies |

| Half-life | Not established for biological extracts |

| Tmax | 15-30 minutes (local reaction) |

| Metabolism | Proteolytic degradation in tissues |

| Excretion | Renal/Biliary (as metabolites) |

The extract is a complex mixture of proteins, glycoproteins, and polysaccharides. The molecular weights of the primary allergens typically range from 10 to 70 kDa. It is soluble in aqueous buffers and is often stabilized with 50% glycerin for long-term storage. The chemical composition can vary slightly between batches, which is why it is classified as 'Non-Standardized.'

Matricaria Chamomilla Flowering Top is classified as an Allergenic Extract. It belongs to the sub-class of Non-Standardized Food and Plant Extracts. Related medications include extracts for Ragweed, Timothy Grass, and various tree pollens used in similar diagnostic and therapeutic capacities.